OneSource

Highly Engaged Employees

OneSource Specialty Pharma Limited is a multimodal specialty pharmaceutical contract development and manufacturing organization headquartered in Bengaluru, India. Formed through the merger of three CDMO businesses within the Strides Group, specifically Stelis Biopharma's Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin... businesses, OneSource was officially launched at CPHI Milan in 2024. The company operates five state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including the US FDA, European Union authorities, and the Therapeutic Goods Administration. With over 30 years of manufacturing and quality excellence, OneSource employs more than 1,200 professionals, including over 200 techno-commercial experts, and serves more than 50 global pharmaceutical and biotechnology clients. The company specializes in end-to-end capabilities across multiple technology platforms and therapeutic modalities, including biologics drug substance and drug product manufacturing, drug-device combinations such as prefilled syringes and autoinjectors, complex sterile injectables, and soft gelatin capsules. OneSource has the capacity to produce over 100 million injectable doses and 2.4 billion soft gelatin capsules annually, with its flagship Bangalore site being one of the few facilities globally capable of manufacturing both biologics drug substance and drug product on the same premises. The company holds 35 approved Abbreviated New Drug Applications and has 19 commercialized drug products in the United States. Led by CEO Neeraj Sharma and Chief Quality Officer Bernhard Thurnbauer, OneSource is positioned to capitalize on growing demand for GLP-1 drug-device combinations and supply chain diversification driven by the BIOSECURE Act, projecting 32 percent revenue growth in 2025 with sales expected to reach 400 million dollars by 2028.Read More